CME

Host: John P. Leonard, MD

Guest: Sarah Rutherford, MD

This series of bite-sized episodes will provide important information in the evolving world of bispecific antibodies and antibody-drug conjugates for the treatment of lymphoma. Join our team of experts as they tackle the recent treatment advances in Hodgkin, follicular, and diffuse large B-cell lymphoma.

On May 19, 2023, the FDA granted accelerated approval to epcoritamab-bysp (Epkinly) for relapsed or refractory diffuse large B-cell lymphoma not otherwise specified, including diffuse large B-cell lymphoma arising from indolent lymphoma, and high-grade B-cell lymphoma after two or more lines of systemic therapy. To learn more about this approval, please visit: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-epkinly-epcoritamab-bysp-relapsed-or-refractory-diffuse-large-b#:~:text=On%20May%2019%2C%202023%2C%20the,or%20more%20lines%20of%20systemic

On June 15, 2023, the FDA granted accelerated approval to glofitamab-gxbm (Columvi) for relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS) or large B-cell lymphoma (LBCL) arising from follicular lymphoma, after two or more lines of systemic therapy. To learn more about this approval please visit: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-glofitamab-gxbm-selected-relapsed-or-refractory-large-b-cell

Host: Kami Maddocks, MD

Guest: Matthew J. Matasar, MD

This series of bite-sized episodes will provide important information in the evolving world of bispecific antibodies and antibody-drug conjugates for the treatment of lymphoma. Join our team of experts as they tackle the recent treatment advances in Hodgkin, follicular, and diffuse large B-cell lymphoma.

On May 19, 2023, the FDA granted accelerated approval to epcoritamab-bysp (Epkinly) for relapsed or refractory diffuse large B-cell lymphoma not otherwise specified, including diffuse large B-cell lymphoma arising from indolent lymphoma, and high-grade B-cell lymphoma after two or more lines of systemic therapy. To learn more about this approval, please visit: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-epkinly-epcoritamab-bysp-relapsed-or-refractory-diffuse-large-b#:~:text=On%20May%2019%2C%202023%2C%20the,or%20more%20lines%20of%20systemic

On June 15, 2023, the FDA granted accelerated approval to glofitamab-gxbm (Columvi) for relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS) or large B-cell lymphoma (LBCL) arising from follicular lymphoma, after two or more lines of systemic therapy. To learn more about this approval please visit: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-glofitamab-gxbm-selected-relapsed-or-refractory-large-b-cell

Host: Kami Maddocks, MD

Guest: Matthew J. Matasar, MD

This series of bite-sized episodes will provide important information in the evolving world of bispecific antibodies and antibody-drug conjugates for the treatment of lymphoma. Join our team of experts as they tackle the recent treatment advances in Hodgkin, follicular, and diffuse large B-cell lymphoma.

On May 19, 2023, the FDA granted accelerated approval to epcoritamab-bysp (Epkinly) for relapsed or refractory diffuse large B-cell lymphoma not otherwise specified, including diffuse large B-cell lymphoma arising from indolent lymphoma, and high-grade B-cell lymphoma after two or more lines of systemic therapy. To learn more about this approval, please visit: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-epkinly-epcoritamab-bysp-relapsed-or-refractory-diffuse-large-b#:~:text=On%20May%2019%2C%202023%2C%20the,or%20more%20lines%20of%20systemic

On June 15, 2023, the FDA granted accelerated approval to glofitamab-gxbm (Columvi) for relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS) or large B-cell lymphoma (LBCL) arising from follicular lymphoma, after two or more lines of systemic therapy. To learn more about this approval please visit: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-glofitamab-gxbm-selected-relapsed-or-refractory-large-b-cell

Host: Lee P. Shulman, MD, FACMG, FACOG

Guest: Roberto Romero, MD, DMedSci

This program is no longer available for credit.

Renowned international expert Dr. Roberto Romero joins Dr. Lee Shulman to walk us through maternal anti-fetal rejection. Find out about its pathophysiology, mechanisms of disease, approach to diagnosis, and potential treatment so that you can broaden your understanding and improve the care you provide.

Host: Vikram Anand, MD, PhD

This program discusses respiratory syncytial virus (RSV), a ubiquitous infection capable of infecting all age groups with a high probability of reinfection. However, the clinical presentation of the disease across age groups is non-specific, and clinicians often fail to identify individuals within the population at the highest risk for poor outcomes. RSV vaccination attempts have historically been unsuccessful. Multiple potential vaccines are proceeding to the late stage of development; however, there is little awareness of these potential options. This program addresses these topics, as well as vaccine hesitancy, as it is often a barrier to improving vaccination compliance, as it exists both at the provider and patient level.

Host: Eric A. F. Simões, MB, BS, DCH, MD

This program discusses respiratory syncytial virus (RSV), a ubiquitous infection capable of infecting all age groups with a high probability of reinfection. However, the clinical presentation of the disease across age groups is non-specific, and clinicians often fail to identify individuals within the population at the highest risk for poor outcomes. RSV vaccination attempts have historically been unsuccessful. Multiple potential vaccines are proceeding to the late stage of development; however, there is little awareness of these potential options. This program addresses these topics, as well as vaccine hesitancy, as it is often a barrier to improving vaccination compliance, as it exists both at the provider and patient level.

Host: Eric A. F. Simões, MB, BS, DCH, MD

This program discusses respiratory syncytial virus (RSV), a ubiquitous infection capable of infecting all age groups with a high probability of reinfection. However, the clinical presentation of the disease across age groups is non-specific, and clinicians often fail to identify individuals within the population at the highest risk for poor outcomes. RSV vaccination attempts have historically been unsuccessful. Multiple potential vaccines are proceeding to the late stage of development; however, there is little awareness of these potential options. This program addresses these topics, as well as vaccine hesitancy, as it is often a barrier to improving vaccination compliance, as it exists both at the provider and patient level.

Host: Priya Soni, MD, FAAP

This program discusses respiratory syncytial virus (RSV), a ubiquitous infection capable of infecting all age groups with a high probability of reinfection. However, the clinical presentation of the disease across age groups is non-specific, and clinicians often fail to identify individuals within the population at the highest risk for poor outcomes. RSV vaccination attempts have historically been unsuccessful. Multiple potential vaccines are proceeding to the late stage of development; however, there is little awareness of these potential options. This program addresses these topics, as well as vaccine hesitancy, as it is often a barrier to improving vaccination compliance, as it exists both at the provider and patient level.

Host: Vikram Anand, MD, PhD

This program discusses respiratory syncytial virus (RSV), a ubiquitous infection capable of infecting all age groups with a high probability of reinfection. However, the clinical presentation of the disease across age groups is non-specific, and clinicians often fail to identify individuals within the population at the highest risk for poor outcomes. RSV vaccination attempts have historically been unsuccessful. Multiple potential vaccines are proceeding to the late stage of development; however, there is little awareness of these potential options. This program addresses these topics, as well as vaccine hesitancy, as it is often a barrier to improving vaccination compliance, as it exists both at the provider and patient level.

Host: Vikram Anand, MD, PhD

Guest: Priya Soni, MD, FAAP

This program discusses respiratory syncytial virus (RSV), a ubiquitous infection capable of infecting all age groups with a high probability of reinfection. However, the clinical presentation of the disease across age groups is non-specific, and clinicians often fail to identify individuals within the population at the highest risk for poor outcomes. RSV vaccination attempts have historically been unsuccessful. Multiple potential vaccines are proceeding to the late stage of development; however, there is little awareness of these potential options. This program addresses these topics, as well as vaccine hesitancy, as it is often a barrier to improving vaccination compliance, as it exists both at the provider and patient level.